. 2014 Mar 19;14:147. doi: 10.1186/1471-2334-14-147

Table 4.

Analysis of lymphocyte subsets in the different groups at the acute phase (AP) and receding pandemic (CP) phases

Lymphocyte subsets	Healthy controls (n = 30)	Phase	Silent infection (n = 30)	Minor infection (n = 27)	Severe infection (n = 34)	P -value
mDC/PBMC, %	0.53 ± 0.13	AP	1.09 ± 0.34^b	0.81 ± 0.48^b,c	0.53 ± 0.24^c,d	<0.0001^a
mDC/PBMC, %	0.53 ± 0.13	CP	0.89 ± 0.43^b,e	ND	0.70 ± 0.30^e	0.0014^a
pDC/PBMC, %	0.24 ± 0.11	AP	0.42 ± 0.21^b	0.39 ± 0.23^b	0.22 ± 0.14^c,d	<0.0001^a
pDC/PBMC, %	0.24 ± 0.11	CP	0.37 ± 0.22^b	ND	0.38 ± 0.12^b,e	0.0048^a
IFN-γ⁺CD4/CD3, %	23.09 ± 6.03	AP	17.41 ± 7.75^b	16.13 ± 5.60^b,d	23.94 ± 6.72^c,d	<0.0001^a
IFN-γ⁺CD4/CD3, %	23.09 ± 6.03	CP	23.38 ± 6.81^e	ND	24.50 ± 8.73	0.0001^a
IFN-γ + CD8/CD3, %	14.30 ± 5.65	AP	15.88 ± 8.17	12.53 ± 6.33	18.30 ± 8.23	0.0251
IFN-γ + CD8/CD3, %	14.30 ± 5.65	CP	23.30 ± 8.94^b,e	ND	18.40 ± 8.66^d	0.0003^a
IL-17⁺CD4/CD3, %	2.06 ± 0.94	AP	1.74 ± 0.96	1.93 ± 0.89^d	2.84 ± 1.19^b,c,d	0.0004^a
IL-17⁺CD4/CD3, %	2.06 ± 0.94	CP	3.37 ± 1.47^b,e	ND	3.04 ± 1.36^b	0.0002^a
IL-17⁺CD8/CD3, %	0.22 ± 0.17	AP	0.54 ± 0.33^b	0.40 ± 0.22^b,d	0.25 ± 0.18^c	<0.0001^a
		CP	0.81 ± 0.34^b	ND	0.74 ± 0.69^b	<0.0001^a

DC, dendritic cell; AP, acute phase; PBMC, peripheral blood mononuclear cell; CP, convalescent phase; ND, not determined.

^asignificant differences in the four groups by one-way ANOVA.

^bsignificant difference from the healthy control group.

^csignificant difference from the silent infection group.

^dsignificant difference from the minor infection group.

^esignificant difference from the AP within a group.